These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 22961547)

  • 41. Lafora disease proteins laforin and malin negatively regulate the HIPK2-p53 cell death pathway.
    Upadhyay M; Gupta S; Bhadauriya P; Ganesh S
    Biochem Biophys Res Commun; 2015 Aug; 464(1):106-11. PubMed ID: 26102034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.
    López-González I; Viana R; Sanz P; Ferrer I
    Mol Neurobiol; 2017 Jul; 54(5):3119-3130. PubMed ID: 27041370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Lafora's disease presenting with progressive myoclonus epilepsy].
    Béjot Y; Lemesle-Martin M; Contégal F; Graule-Petot A; Thauvin C; Aubriot-Lorton MH; Moreau T; Giroud M
    Rev Neurol (Paris); 2007 Oct; 163(10):975-8. PubMed ID: 18033035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
    Gentry MS; Worby CA; Dixon JE
    Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8501-6. PubMed ID: 15930137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease.
    Kumarasinghe L; Garcia-Gimeno MA; Ramirez J; Mayor U; Zugaza JL; Sanz P
    Neurobiol Dis; 2023 Feb; 177():105998. PubMed ID: 36638890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel EPM2A mutation yields a slow progression form of Lafora disease.
    Garcia-Gimeno MA; Rodilla-Ramirez PN; Viana R; Salas-Puig X; Brewer MK; Gentry MS; Sanz P
    Epilepsy Res; 2018 Sep; 145():169-177. PubMed ID: 30041081
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.
    Dubey D; Ganesh S
    Hum Mol Genet; 2008 Oct; 17(19):3010-20. PubMed ID: 18617530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lafora Disease: A Ubiquitination-Related Pathology.
    García-Gimeno MA; Knecht E; Sanz P
    Cells; 2018 Jul; 7(8):. PubMed ID: 30050012
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epm2a
    Burgos DF; Sciaccaluga M; Worby CA; Zafra-Puerta L; Iglesias-Cabeza N; Sánchez-Martín G; Prontera P; Costa C; Serratosa JM; Sánchez MP
    Neurobiol Dis; 2023 Jun; 181():106119. PubMed ID: 37059210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutations in NHLRC1 cause progressive myoclonus epilepsy.
    Chan EM; Young EJ; Ianzano L; Munteanu I; Zhao X; Christopoulos CC; Avanzini G; Elia M; Ackerley CA; Jovic NJ; Bohlega S; Andermann E; Rouleau GA; Delgado-Escueta AV; Minassian BA; Scherer SW
    Nat Genet; 2003 Oct; 35(2):125-7. PubMed ID: 12958597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endocytosis of the glutamate transporter 1 is regulated by laforin and malin: Implications in Lafora disease.
    Perez-Jimenez E; Viana R; Muñoz-Ballester C; Vendrell-Tornero C; Moll-Diaz R; Garcia-Gimeno MA; Sanz P
    Glia; 2021 May; 69(5):1170-1183. PubMed ID: 33368637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.
    Ortolano S; Vieitez I; Agis-Balboa RC; Spuch C
    Mol Brain; 2014 Jan; 7():7. PubMed ID: 24472629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Utilization of skin biopsy for diagnosis in a case of Lafora disease.
    Rozenova KA; Lehman JS; Grande JP; Fine AL; Wieland CN
    J Cutan Pathol; 2022 Oct; 49(10):885-888. PubMed ID: 35708461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice.
    Zafra-Puerta L; Colpaert M; Iglesias-Cabeza N; Burgos DF; Sánchez-Martín G; Gentry MS; Sánchez MP; Serratosa JM
    Epilepsy Res; 2024 Feb; 200():107317. PubMed ID: 38341935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
    Rao SN; Sharma J; Maity R; Jana NR
    J Biol Chem; 2010 Jan; 285(2):1404-13. PubMed ID: 19892702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
    Nitschke F; Sullivan MA; Wang P; Zhao X; Chown EE; Perri AM; Israelian L; Juana-López L; Bovolenta P; Rodríguez de Córdoba S; Steup M; Minassian BA
    EMBO Mol Med; 2017 Jul; 9(7):906-917. PubMed ID: 28536304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.
    Sánchez-Elexpuru G; Serratosa JM; Sanz P; Sánchez MP
    Neuroreport; 2017 Mar; 28(5):268-271. PubMed ID: 28181916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
    Delgado-Escueta AV; Bourgeois BF
    Epilepsia; 2008 Dec; 49 Suppl 9():13-24. PubMed ID: 19087113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Myoclonic epilepsy of Lafora: a case report].
    Rudenskaia GE; Zakharova EIu; Karpin SL; Uchaev DA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3 Suppl 2):11-6. PubMed ID: 20873469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy.
    Ganesh S; Puri R; Singh S; Mittal S; Dubey D
    J Hum Genet; 2006; 51(1):1-8. PubMed ID: 16311711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.